APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Invasive Cancer Detection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-Invasive Cancer Detection Market Analysis and Forecast 2026-2032

5 June 2026241 pages

Choose your research edition.

Industry ResearchNon-Invasive Cancer Detection Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Invasive Cancer Detection Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Non-Invasive Cancer Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Invasive Cancer Detection Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Invasive Cancer Detection Market Analysis and Forecast 2026-2032241 pages · $4,950 USD

Market perspective

The global Non-Invasive Cancer Detection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-Invasive Cancer Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-Invasive Cancer Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-Invasive Cancer Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-Invasive Cancer Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-Invasive Cancer Detection include Trublood, Datar Cancer Genetics, Nucleix, miR Scientific, Owlstone Medical, bioAffinity Technologies, Nonacus and Amadix, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-Invasive Cancer Detection, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-Invasive Cancer Detection, also provides the revenue of main regions and countries. Of the upcoming market potential for Non-Invasive Cancer Detection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-Invasive Cancer Detection revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-Invasive Cancer Detection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-Invasive Cancer Detection revenue, projected growth trends, production technology, application and end-user industry.

Non-Invasive Cancer Detection Segment by Company

Trublood

Datar Cancer Genetics

Nucleix

miR Scientific

Owlstone Medical

bioAffinity Technologies

Nonacus

Amadix

Non-Invasive Cancer Detection Segment by Type

Imaging Test

Nuclear Medicine Test

Others

Non-Invasive Cancer Detection Segment by Application

Prostate Cancer

Bladder Cancer

Pancreatic Cancer

Breast Cancer

Gastric Cancer

Others

Non-Invasive Cancer Detection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Invasive Cancer Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Invasive Cancer Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Invasive Cancer Detection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-Invasive Cancer Detection in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-Invasive Cancer Detection company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Invasive Cancer Detection revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-Invasive Cancer Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Imaging Test Major Player Table 3. Nuclear Medicine Test Major Player Table 4. Others Major Player Table 5. Global Non-Invasive Cancer Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Prostate Cancer Major Player Table 7. Bladder Cancer Major Player Table 8. Pancreatic Cancer Major Player Table 9. Breast Cancer Major Player Table 10. Gastric Cancer Major Player Table 11. Others Major Player Table 12. Non-Invasive Cancer Detection Industry Trends Table 13. Non-Invasive Cancer Detection Industry Drivers Table 14. Non-Invasive Cancer Detection Industry Opportunities and Challenges Table 15. Non-Invasive Cancer Detection Industry Restraints Table 16. Global Non-Invasive Cancer Detection Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Non-Invasive Cancer Detection Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Non-Invasive Cancer Detection Market Share by Region (2021-2026) Table 19. Global Non-Invasive Cancer Detection Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Non-Invasive Cancer Detection Market Share by Region (2027-2032) Table 21. Global Non-Invasive Cancer Detection Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Non-Invasive Cancer Detection Revenue Market Share by Players (2021-2026) Table 23. Global Non-Invasive Cancer Detection Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Non-Invasive Cancer Detection Key Players Headquarters & Area Served Table 25. Global Non-Invasive Cancer Detection Players, Product Type & Application Table 26. Global Non-Invasive Cancer Detection Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Non-Invasive Cancer Detection by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Non-Invasive Cancer Detection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Non-Invasive Cancer Detection Revenue Market Share by Type (2021-2026) Table 33. Global Non-Invasive Cancer Detection Revenue Market Share by Type (2027-2032) Table 34. Global Non-Invasive Cancer Detection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Non-Invasive Cancer Detection Revenue Market Share by Application (2021-2026) Table 38. Global Non-Invasive Cancer Detection Revenue Market Share by Application (2027-2032) Table 39. Trublood Company Information Table 40. Trublood Business Overview Table 41. Trublood Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Trublood Non-Invasive Cancer Detection Product Portfolio Table 43. Trublood Recent Development Table 44. Datar Cancer Genetics Company Information Table 45. Datar Cancer Genetics Business Overview Table 46. Datar Cancer Genetics Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Datar Cancer Genetics Non-Invasive Cancer Detection Product Portfolio Table 48. Datar Cancer Genetics Recent Development Table 49. Nucleix Company Information Table 50. Nucleix Business Overview Table 51. Nucleix Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Nucleix Non-Invasive Cancer Detection Product Portfolio Table 53. Nucleix Recent Development Table 54. miR Scientific Company Information Table 55. miR Scientific Business Overview Table 56. miR Scientific Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. miR Scientific Non-Invasive Cancer Detection Product Portfolio Table 58. miR Scientific Recent Development Table 59. Owlstone Medical Company Information Table 60. Owlstone Medical Business Overview Table 61. Owlstone Medical Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Owlstone Medical Non-Invasive Cancer Detection Product Portfolio Table 63. Owlstone Medical Recent Development Table 64. bioAffinity Technologies Company Information Table 65. bioAffinity Technologies Business Overview Table 66. bioAffinity Technologies Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. bioAffinity Technologies Non-Invasive Cancer Detection Product Portfolio Table 68. bioAffinity Technologies Recent Development Table 69. Nonacus Company Information Table 70. Nonacus Business Overview Table 71. Nonacus Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nonacus Non-Invasive Cancer Detection Product Portfolio Table 73. Nonacus Recent Development Table 74. Amadix Company Information Table 75. Amadix Business Overview Table 76. Amadix Non-Invasive Cancer Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Amadix Non-Invasive Cancer Detection Product Portfolio Table 78. Amadix Recent Development Table 79. North America Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 80. North America Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 81. North America Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 82. North America Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 83. North America Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America Non-Invasive Cancer Detection Revenue by Country (2021-2026) & (US$ Million) Table 85. North America Non-Invasive Cancer Detection Revenue by Country (US$ Million) & (2027-2032) Table 86. Europe Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 87. Europe Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 88. Europe Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 89. Europe Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 90. Europe Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Europe Non-Invasive Cancer Detection Revenue by Country (2021-2026) & (US$ Million) Table 92. Europe Non-Invasive Cancer Detection Revenue by Country (US$ Million) & (2027-2032) Table 93. China Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 94. China Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 95. China Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 96. China Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 98. Asia Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 99. Asia Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 100. Asia Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Non-Invasive Cancer Detection Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Asia Non-Invasive Cancer Detection Revenue by Region (US$ Million) & (2021-2026) Table 103. Asia Non-Invasive Cancer Detection Revenue by Region (US$ Million) & (2027-2032) Table 104. SAMEA Non-Invasive Cancer Detection Revenue by Type (2021-2026) & (US$ Million) Table 105. SAMEA Non-Invasive Cancer Detection Revenue by Type (2027-2032) & (US$ Million) Table 106. SAMEA Non-Invasive Cancer Detection Revenue by Application (2021-2026) & (US$ Million) Table 107. SAMEA Non-Invasive Cancer Detection Revenue by Application (2027-2032) & (US$ Million) Table 108. SAMEA Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. SAMEA Non-Invasive Cancer Detection Revenue by Country (2021-2026) & (US$ Million) Table 110. SAMEA Non-Invasive Cancer Detection Revenue by Country (US$ Million) & (2027-2032) Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Non-Invasive Cancer Detection Image Figure 2. Global Non-Invasive Cancer Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Invasive Cancer Detection Market Size Share 2021 VS 2025 VS 2032 Figure 4. Imaging Test Image Figure 5. Nuclear Medicine Test Image Figure 6. Others Image Figure 7. Global Non-Invasive Cancer Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Non-Invasive Cancer Detection Market Size Share 2021 VS 2025 VS 2032 Figure 9. Prostate Cancer Image Figure 10. Bladder Cancer Image Figure 11. Pancreatic Cancer Image Figure 12. Breast Cancer Image Figure 13. Gastric Cancer Image Figure 14. Others Image Figure 15. Global Non-Invasive Cancer Detection Market Size (US$ Million) & (2021-2032) Figure 16. Global Non-Invasive Cancer Detection Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Non-Invasive Cancer Detection Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Non-Invasive Cancer Detection Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Non-Invasive Cancer Detection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Non-Invasive Cancer Detection Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Non-Invasive Cancer Detection Revenue Market Share by Type (2021-2032) Figure 23. Global Non-Invasive Cancer Detection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Non-Invasive Cancer Detection Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Non-Invasive Cancer Detection Revenue Market Share by Application (2021-2032) Figure 26. North America Non-Invasive Cancer Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Non-Invasive Cancer Detection Revenue Share by Type (2021-2032) Figure 28. North America Non-Invasive Cancer Detection Revenue Share by Application (2021-2032) Figure 29. North America Non-Invasive Cancer Detection Revenue Share by Country (2021-2032) Figure 30. United States Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Non-Invasive Cancer Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Non-Invasive Cancer Detection Revenue Share by Type (2021-2032) Figure 35. Europe Non-Invasive Cancer Detection Revenue Share by Application (2021-2032) Figure 36. Europe Non-Invasive Cancer Detection Revenue Share by Country (2021-2032) Figure 37. Germany Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Non-Invasive Cancer Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Non-Invasive Cancer Detection Revenue Share by Type (2021-2032) Figure 47. China Non-Invasive Cancer Detection Revenue Share by Application (2021-2032) Figure 48. Asia Non-Invasive Cancer Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Non-Invasive Cancer Detection Revenue Share by Type (2021-2032) Figure 50. Asia Non-Invasive Cancer Detection Revenue Share by Application (2021-2032) Figure 51. Asia Non-Invasive Cancer Detection Revenue Share by Region (2021-2032) Figure 52. Japan Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Non-Invasive Cancer Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Non-Invasive Cancer Detection Revenue Share by Type (2021-2032) Figure 60. SAMEA Non-Invasive Cancer Detection Revenue Share by Application (2021-2032) Figure 61. SAMEA Non-Invasive Cancer Detection Revenue Share by Country (2021-2032) Figure 62. Brazil Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Non-Invasive Cancer Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Imaging Test
  • Nuclear Medicine Test
  • Others
Applications
  • Prostate Cancer
  • Bladder Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
Companies covered
  • Trublood
  • Datar Cancer Genetics
  • Nucleix
  • miR Scientific
  • Owlstone Medical
  • bioAffinity Technologies
  • Nonacus
  • Amadix

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-Invasive Cancer Detection Market by Type
  3. 1.2.1 Global Non-Invasive Cancer Detection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Imaging Test
  5. 1.2.3 Nuclear Medicine Test
  6. 1.2.4 Others
  7. 1.3 Non-Invasive Cancer Detection Market by Application
  8. 1.3.1 Global Non-Invasive Cancer Detection Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Prostate Cancer
  10. 1.3.3 Bladder Cancer
  11. 1.3.4 Pancreatic Cancer
  12. 1.3.5 Breast Cancer
  13. 1.3.6 Gastric Cancer
  14. 1.3.7 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Non-Invasive Cancer Detection Market Dynamics
  1. 2.1 Non-Invasive Cancer Detection Industry Trends
  2. 2.2 Non-Invasive Cancer Detection Industry Drivers
  3. 2.3 Non-Invasive Cancer Detection Industry Opportunities and Challenges
  4. 2.4 Non-Invasive Cancer Detection Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-Invasive Cancer Detection Market Perspective (2021-2032)
  2. 3.2 Global Non-Invasive Cancer Detection Growth Trends by Region
  3. 3.2.1 Global Non-Invasive Cancer Detection Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-Invasive Cancer Detection Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-Invasive Cancer Detection Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-Invasive Cancer Detection Revenue by Players
  2. 4.1.1 Global Non-Invasive Cancer Detection Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-Invasive Cancer Detection Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-Invasive Cancer Detection Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-Invasive Cancer Detection Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-Invasive Cancer Detection Key Players Headquarters & Area Served
  7. 4.4 Global Non-Invasive Cancer Detection Players, Product Type & Application
  8. 4.5 Global Non-Invasive Cancer Detection Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-Invasive Cancer Detection Market CR5 and HHI
  11. 4.6.3 2025 Non-Invasive Cancer Detection Tier 1, Tier 2, and Tier 3
5 Non-Invasive Cancer Detection Market Size by Type
  1. 5.1 Global Non-Invasive Cancer Detection Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 5.3 Global Non-Invasive Cancer Detection Revenue Market Share by Type (2021-2032)
6 Non-Invasive Cancer Detection Market Size by Application
  1. 6.1 Global Non-Invasive Cancer Detection Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  3. 6.3 Global Non-Invasive Cancer Detection Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Trublood
  2. 7.1.1 Trublood Company Information
  3. 7.1.2 Trublood Business Overview
  4. 7.1.3 Trublood Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Trublood Non-Invasive Cancer Detection Product Portfolio
  6. 7.1.5 Trublood Recent Developments
  7. 7.2 Datar Cancer Genetics
  8. 7.2.1 Datar Cancer Genetics Company Information
  9. 7.2.2 Datar Cancer Genetics Business Overview
  10. 7.2.3 Datar Cancer Genetics Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Datar Cancer Genetics Non-Invasive Cancer Detection Product Portfolio
  12. 7.2.5 Datar Cancer Genetics Recent Developments
  13. 7.3 Nucleix
  14. 7.3.1 Nucleix Company Information
  15. 7.3.2 Nucleix Business Overview
  16. 7.3.3 Nucleix Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Nucleix Non-Invasive Cancer Detection Product Portfolio
  18. 7.3.5 Nucleix Recent Developments
  19. 7.4 miR Scientific
  20. 7.4.1 miR Scientific Company Information
  21. 7.4.2 miR Scientific Business Overview
  22. 7.4.3 miR Scientific Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  23. 7.4.4 miR Scientific Non-Invasive Cancer Detection Product Portfolio
  24. 7.4.5 miR Scientific Recent Developments
  25. 7.5 Owlstone Medical
  26. 7.5.1 Owlstone Medical Company Information
  27. 7.5.2 Owlstone Medical Business Overview
  28. 7.5.3 Owlstone Medical Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Owlstone Medical Non-Invasive Cancer Detection Product Portfolio
  30. 7.5.5 Owlstone Medical Recent Developments
  31. 7.6 bioAffinity Technologies
  32. 7.6.1 bioAffinity Technologies Company Information
  33. 7.6.2 bioAffinity Technologies Business Overview
  34. 7.6.3 bioAffinity Technologies Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  35. 7.6.4 bioAffinity Technologies Non-Invasive Cancer Detection Product Portfolio
  36. 7.6.5 bioAffinity Technologies Recent Developments
  37. 7.7 Nonacus
  38. 7.7.1 Nonacus Company Information
  39. 7.7.2 Nonacus Business Overview
  40. 7.7.3 Nonacus Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nonacus Non-Invasive Cancer Detection Product Portfolio
  42. 7.7.5 Nonacus Recent Developments
  43. 7.8 Amadix
  44. 7.8.1 Amadix Company Information
  45. 7.8.2 Amadix Business Overview
  46. 7.8.3 Amadix Non-Invasive Cancer Detection Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amadix Non-Invasive Cancer Detection Product Portfolio
  48. 7.8.5 Amadix Recent Developments
8 North America
  1. 8.1 North America Non-Invasive Cancer Detection Revenue (2021-2032)
  2. 8.2 North America Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-Invasive Cancer Detection Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-Invasive Cancer Detection Revenue by Type (2027-2032)
  5. 8.3 North America Non-Invasive Cancer Detection Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-Invasive Cancer Detection Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-Invasive Cancer Detection Revenue by Application (2027-2032)
  9. 8.5 North America Non-Invasive Cancer Detection Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-Invasive Cancer Detection Revenue by Country
  11. 8.6.1 North America Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-Invasive Cancer Detection Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-Invasive Cancer Detection Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Non-Invasive Cancer Detection Revenue (2021-2032)
  2. 9.2 Europe Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-Invasive Cancer Detection Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-Invasive Cancer Detection Revenue by Type (2027-2032)
  5. 9.3 Europe Non-Invasive Cancer Detection Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-Invasive Cancer Detection Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-Invasive Cancer Detection Revenue by Application (2027-2032)
  9. 9.5 Europe Non-Invasive Cancer Detection Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-Invasive Cancer Detection Revenue by Country
  11. 9.6.1 Europe Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-Invasive Cancer Detection Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-Invasive Cancer Detection Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Non-Invasive Cancer Detection Revenue (2021-2032)
  2. 10.2 China Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 10.2.1 China Non-Invasive Cancer Detection Revenue by Type (2021-2026)
  4. 10.2.2 China Non-Invasive Cancer Detection Revenue by Type (2027-2032)
  5. 10.3 China Non-Invasive Cancer Detection Revenue Share by Type (2021-2032)
  6. 10.4 China Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  7. 10.4.1 China Non-Invasive Cancer Detection Revenue by Application (2021-2026)
  8. 10.4.2 China Non-Invasive Cancer Detection Revenue by Application (2027-2032)
  9. 10.5 China Non-Invasive Cancer Detection Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-Invasive Cancer Detection Revenue (2021-2032)
  2. 11.2 Asia Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-Invasive Cancer Detection Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-Invasive Cancer Detection Revenue by Type (2027-2032)
  5. 11.3 Asia Non-Invasive Cancer Detection Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-Invasive Cancer Detection Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-Invasive Cancer Detection Revenue by Application (2027-2032)
  9. 11.5 Asia Non-Invasive Cancer Detection Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-Invasive Cancer Detection Revenue by Country
  11. 11.6.1 Asia Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-Invasive Cancer Detection Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-Invasive Cancer Detection Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-Invasive Cancer Detection Revenue (2021-2032)
  2. 12.2 SAMEA Non-Invasive Cancer Detection Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-Invasive Cancer Detection Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-Invasive Cancer Detection Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-Invasive Cancer Detection Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-Invasive Cancer Detection Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-Invasive Cancer Detection Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-Invasive Cancer Detection Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-Invasive Cancer Detection Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-Invasive Cancer Detection Revenue by Country
  11. 12.6.1 SAMEA Non-Invasive Cancer Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-Invasive Cancer Detection Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-Invasive Cancer Detection Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst